Sexual and reproductive health
Melanotan-2 (MT-2)
Also called MT-II, MT-2
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Quick start
Melanotan-2 (MT-2) at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.7–2.1 mg per administration
- How often
- 5 days on, 2 off
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Timing
- Often a small evening dose during a short loading period, then less often to maintain.
- What people report
- Pigment changes are discussed over one to several weeks and depend on sun exposure.
- Time to steady level
- ~8 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- loading then maintenance
- Break between
- as desired Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C50H69N15O9
- Mol. weight
- 1,024.2 Da
- CAS
- 121062-08-6
- PubChem CID
- 92432
External references
Structure note
A diagram is a reference representation of the named chemical structure. It does not establish the composition, purity, or identity of any particular vial.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Melanotan-2 (MT-2) describe 0.7–2.1 mg per administration. Descriptive only, not a recommendation.
Roughly 1–2 hours, but poorly characterized; published estimates vary.
The one human dosing source is a three-subject 1996 safety pilot (Dorr), not a dose-ranging trial, so the tier-A grade and the schedule below both rest on an n=3 sample and should be read as provisional.
Dosing schedule
How Melanotan-2 (MT-2) is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported rangeA melanocortin agonist. These amounts come from a three-subject 1996 pilot; the sample is far too small to fix a schedule. | 0.01–0.03 mg/kg (about 0.7–2.1 mg for a 70 kg adult) | Once daily, Monday–Friday | SubQ |
What it can be combined with
How Melanotan-2 (MT-2) is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- PT-141Both are melanocortin-receptor agonists, so combining them intensifies shared effects such as nausea and flushing.Use caution
Modelled level — 5 days on, 2 off
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 8hours
- Administrations
- 5/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Dorr RT et al., Life Sci 1996;58:1777A three-subject safety pilot of melanotan-II given subcutaneously at 0.01–0.03 mg/kg on a weekday schedule.